Ieq Capital LLC Takes $288,000 Position in AMNEAL PHARMACEUTICALS, INC. $AMRX

Key Points

• Ieq Capital LLC has purchased 34,327 shares in AMNEAL PHARMACEUTICALS, valued at approximately $288,000, according to its recent SEC filing.
• Several hedge funds, including Vanguard Group and Walleye Capital, have significantly increased their stakes in AMNEAL PHARMACEUTICALS during the first quarter.
• AMNEAL PHARMACEUTICALS reported an EPS of $0.23 for its last quarter, exceeding analyst estimates, and is projecting FY 2025 guidance of 0.700-0.750 EPS.

Ieq Capital LLC acquired a new stake in shares of AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 34,327 shares of the company's stock, valued at approximately $288,000.

Other hedge funds have also added to or reduced their stakes in the company. Janney Montgomery Scott LLC increased its position in AMNEAL PHARMACEUTICALS by 26.9% during the 1st quarter. Janney Montgomery Scott LLC now owns 19,350 shares of the company's stock valued at $162,000 after purchasing an additional 4,100 shares during the period. Allspring Global Investments Holdings LLC increased its position in AMNEAL PHARMACEUTICALS by 53.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 60,567 shares of the company's stock valued at $508,000 after purchasing an additional 21,079 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in AMNEAL PHARMACEUTICALS by 45.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 318,420 shares of the company's stock valued at $2,522,000 after purchasing an additional 99,866 shares during the period. California State Teachers Retirement System increased its position in AMNEAL PHARMACEUTICALS by 10.3% during the 4th quarter. California State Teachers Retirement System now owns 131,713 shares of the company's stock valued at $1,043,000 after purchasing an additional 12,282 shares during the period. Finally, BNP Paribas Financial Markets increased its position in AMNEAL PHARMACEUTICALS by 209.2% during the 4th quarter. BNP Paribas Financial Markets now owns 168,194 shares of the company's stock valued at $1,332,000 after purchasing an additional 113,796 shares during the period. 31.82% of the stock is owned by hedge funds and other institutional investors.

AMNEAL PHARMACEUTICALS Price Performance

AMRX stock traded up $0.27 during trading on Thursday, hitting $10.09. 2,397,431 shares of the stock traded hands, compared to its average volume of 1,444,133. AMNEAL PHARMACEUTICALS, INC. has a 1 year low of $6.68 and a 1 year high of $10.34. The firm's 50 day moving average is $8.80 and its two-hundred day moving average is $8.18. The stock has a market cap of $3.17 billion, a price-to-earnings ratio of 1,010.01 and a beta of 1.19.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a net margin of 0.12% and a negative return on equity of 189.49%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, analysts anticipate that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group began coverage on shares of AMNEAL PHARMACEUTICALS in a research report on Friday, June 6th. They set a "buy" rating and a $12.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $11.60.

Insider Activity

In related news, Director John Kiely sold 32,000 shares of the stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $9.23, for a total transaction of $295,360.00. Following the sale, the director directly owned 225,433 shares of the company's stock, valued at approximately $2,080,746.59. This represents a 12.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Andrew S. Boyer sold 279,244 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the sale, the executive vice president directly owned 152,426 shares in the company, valued at $1,429,755.88. This trade represents a 64.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 609,206 shares of company stock valued at $5,700,625. Company insiders own 26.56% of the company's stock.

About AMNEAL PHARMACEUTICALS

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.